Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Martello to Report Third Quarter Fiscal 2019 Financial Results
CNW Group
CNW GroupFebruary 21, 2019, 7:45 AM EST
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES ./
OTTAWA , Feb. 21, 2019 /CNW/ - Martello Technologies Group Inc., ("Martello" or the "Company") (MTLO.V), will release its financial results for the third quarter of its 2019 fiscal year, including the three and nine months ended December 31, 2018 before financial markets open on February 26, 2019 .
https://finance.yahoo.com/news/martello-report-third-quarter-fiscal-124500836.html?.tsrc=applewf
Delivra Publishes Positive Results Utilizing its Unique Platform Technology for Topical Doxycycline
https://finance.yahoo.com/news/delivra-publishes-positive-results-utilizing-120000645.html?.tsrc=applewf
CNW Group
February 6, 2019, 7:00 AM EST
TORONTO , Feb. 6, 2019 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company") today announced the publication of positive data from a laboratory and clinical study demonstrating the stability, safety and efficacy to treat diabetic wounds, using Delivra's platform technology, to deliver a topical version of the prescription drug, doxycycline. These results were published in the respected peer-reviewed scientific journal, Wounds Research. This article may be found at the following link: https://www.ncbi.nlm.nih.gov/pubmed/30664497.
A large number of diabetics will develop diabetic leg wounds, which could cause amputation and other complications, which could ultimately result in death. With the aging populations in Canada , USA and Europe , diabetes is becoming a significant problem and is a highly unmet need in medicine today. Delivra continues its significant work in the diabetic field to address this important and growing need.
"This impressive data further validates Delivra's novel technology and offers doctors and their patients an effective, safe and convenient cream for diabetic wounds, without the side effects of oral doxycycline. With a robust pharmaceutical pipeline of high-value innovative products, Delivra-doxycycline formulation provides a unique and growing commercialization opportunity. As such, we will continue to pursue out-licensing opportunities for major global markets to unlock the value of our unique portfolio," said Dr. Joseph Gabriele , CEO of Delivra.
Delivra has filed a provisional patent to protect its unique formulation using doxycycline. DelivraTM topical doxycycline is currently available by prescription across Canada through the compound pharmacy services of NKS Health Ltd.
“The proposals will next go before the UN’s Commission on Narcotic Drugs, potentially as soon as March, where 53 member nations will have the opportunity to vote on accepting or rejecting them.”
This vote might be very interesting
These PP and Bought Deals kinda resemble TWD.v way before when. Me thinks the management strategy bodes well in these times.
Paessler and Martello Announce Strategic Partnership for Enterprise IT Infrastructure Monitoring
https://finance.yahoo.com/news/paessler-martello-announce-strategic-partnership-140000757.html?.tsrc=applewf
PR Newswire
February 4, 2019, 9:00 AM EST
Integration of PRTG Network Monitor with Martello's Savision iQ Provides Network Administrators A Consolidated View of IT Systems and Adds Analytics Capability to Discover, Analyze and Resolve IT Issues to Maximize Uptime
NUREMBERG, Germany, Feb. 4, 2019 /PRNewswire/ -- Paessler AG, the innovative network monitoring specialist, today announced that Savision, a subsidiary of network performance management solutions leader Martello Technologies Group ("Martello") (MTLO.V), has joined the Paessler Uptime Alliance to offer PRTG users a consolidated view of all IT systems from a single dashboard using the Savision iQ software. First announced in April 2018, the alliance is designed to help the company's partners integrate comprehensive, advanced IT infrastructure monitoring in their offerings to help prevent downtime of critical IT systems.
Paessler logo (PRNewsfoto/Paessler AG)
Paessler logo (PRNewsfoto/Paessler AG)
PRTG is an all-in-one unified monitoring solution that makes it easy for IT professionals to know what is happening across their entire IT infrastructure, including networks, systems, hardware, applications and devices, at any point in time. With more than 200,000 installations, PRTG is one of the world's leading IT monitoring solutions.
Martello's Savision iQ software transforms infrastructure and application monitoring data into dashboards that automate and unify IT operations with IT service management workflows. Savision iQ integrates with more than 35 applications, including the PRTG enterprise IT monitoring solution.
The Savision iQ and PRTG out-of-the-box integration provides a solution that discovers, analyzes, and even solves IT issues before they become a problem. The combined solution gathers information from multiple sources such as monitoring tools, cloud platforms, and ITSM systems. PRTG monitors the entire IT suite on a 24/7 basis and sends issues and anomalies to Savision iQ. These issues are correlated and analyzed using automated incident workflows for improved troubleshooting and resolution. Savision iQ is designed to handle a large volume of data, allowing multiple PRTG instances to be rendered and viewed in a single dashboard. This makes the solution suitable for networks of all sizes.
"Martello is delighted to join the Paessler Uptime Alliance Program," says Stefanie Richheimer, chief revenue officer at Martello. "A true technology partnership should benefit customers of both companies, and I believe the combined solution will prove this in the short-term. The combination of best-in-class monitoring with big data analytics and dashboards provides an Enterprise class solution ready for large-scale IT environments."
"It's well-known that system outages seriously impact enterprise bottom-line performance," says Paessler AG CEO Christian Twardawa. "Our Uptime Alliance program offers the opportunity to combine best-of-breed technology, in this case the Savision ITOps solution, with PRTG to not only to detect system failures in the enterprise as soon as they occur, but to also track long term changes in network performance and network usage. It is critical for businesses to identify potential problems before they become a serious threat."
More about Paessler and Savision's partnership and technical integration can be found here:
https://www.savision.com/solutions/integrations/prtg/
https://blog.paessler.com/manage-large-scaled-prtg-environments-with-savision
Canopy Rivers Announces Completion of $17 Million Financing for Its Italian Hemp Platform – Canapar
https://www.newcannabisventures.com/canopy-rivers-boosts-stake-in-italian-hemp-company-with-17-4-million-investment/
TORONTO, Feb. 04, 2019 (GLOBE NEWSWIRE) — Canopy Rivers Inc. (the “Company” or “Canopy Rivers”) (TSXV: RIV) is pleased to announce that it has completed a subsequent $9.4 million equity investment in its portfolio company Canapar Corp. (“Canapar Canada”), the Canadian parent corporation of Canapar SrL (“Canapar Italy”), an Italy-based organic hemp production and processing platform. The investment aligns with the Company’s global-focused growth strategy and is expected to provide the Company with the opportunity to capitalize on the rapidly expanding European cannabidiol (“CBD”) market.
In December 2018, the Company committed to an investment of $17,400,000 in Canapar Canada as part of a $25,000,000 non-brokered private placement. The investments in Canapar Canada have increased the Company’s ownership position from 35% to 49%, on a non-diluted basis.
As previously disclosed, Canapar Italy is a Sicily-based manufacturer and processor of CBD oil and isolates, which are increasingly used as an input into new commercial products in the health and wellness industries. Canapar Italy has secured more than 1,000 hectares of hemp through its outsource farming model and entered into an academic partnership with the University of Catania’s Department of Agriculture. The company is also advancing its CBD extraction and processing capabilities through its new facility and is expecting to transform 600 metric tons of hemp biomass annually into CBD isolates and derivative products for distribution in Europe. With demand for products that contain natural active ingredients derived from plant extracts increasing significantly, Canapar Italy plans on developing CBD-infused cosmetics, skincare, and beauty products for the Italian cosmetics market, which is the fourth largest such market in Europe, as well as the global market, which provides strong demand for “Made in Italy” brands.
Canopy Rivers’ investment in Canapar represents a clear validation of our ability to execute on our strategy and the market opportunity in Europe. We expect to leverage this financing to enhance value for all stakeholders in Canapar and we look forward to a long-term partnership with Canopy Rivers.
Martello Technologies Invites You to Join Us at the Cantech Investment Conference in Toronto
https://finance.yahoo.com/news/martello-technologies-invites-join-us-175600525.html?.tsrc=applewf
January 24, 2019, 12:56 PM EST
Toronto, Ontario--(Newsfile Corp. - January 24, 2019) - Martello Technologies (TSXV: MTLO) would like to cordially invite you to visit us at Booth #522 at the Cantech Investment Conference to be held at the Metro Toronto Convention Centre (255 Front St. West, Toronto) on Tuesday January 29 - Wednesday January 30, 2019.
The Cantech Investment Conference opened the floodgates of capital to Canada's innovation companies. The Conference has grown every year since its inception in 2013 and has been host to every major player in Canadian technology and finance.
This is the hallmark event, that attracts the interest of investors, funds and media from both sides of the border to meet with Canadian innovation entrepreneurs.
For more information and/or to register for the conference please visit: https://cambridgehouse.com/cantech-investment-conference
We look forward to seeing you there.
For further information:
Martello Technologies
Tracy King
613-271-5989 x2112
tking@martellotech.com
martellotech.com
Martello Updates and Extends Agreement with Mitel
https://finance.yahoo.com/news/martello-updates-extends-agreement-mitel-005400655.html?.tsrc=applewf
CNW Group
January 16, 2019, 7:54 PM EST
Longstanding partnership grows with expanded coverage of key Mitel platforms
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES ./
OTTAWA , Jan. 16, 2019 /CNW/ - Martello Technologies Group Inc. (MTLO.V), ("Martello" or the "Company"), a leading provider of network performance management solutions for real-time communications, announced today that it has concluded an amendment to its commercial agreement with Mitel Networks, a key global partner. Updating an agreement signed in April 2016 , the terms of this amendment are expected to be favourable to Martello's revenues, and include expanding the coverage of Martello's software to additional Mitel communications platforms and extending the renewal term. Martello's software is included in Mitel Premium Software Assurance offering in two tiers, Mitel Performance Analytics (MPA) and Mitel Performance Analytics Plus (MPA Plus). This agreement covers the use and resale of MPA software in both tiers.
Delivra publishes positive results utilizing its novel platform technology for Varicose Veins
https://finance.yahoo.com/news/delivra-publishes-positive-results-utilizing-120000097.html?.tsrc=applewf
CNW Group
January 8, 2019, 7:00 AM EST
TORONTO , Jan. 8, 2019 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company") today announced the publication of positive data from a clinical study demonstrating the safety and efficacy to treat chronic venous insufficiency of lower limbs, using the LivReliefTM Varicose Vein Cream over-the-counter product. These results were published in the respected peer-reviewed scientific journal, PLOS ONE. This article may be found at the following link: https://doi.org/10.1371/journal.pone.0208954.
In a human clinical setting, undertaken by an independent third-party medical clinic, LivReliefTM Varicose Vein Cream provided significant therapeutic improvement in the treated lower limbs after six weeks of treatment. In the study, LivReliefTM Varicose Vein Cream was tested in humans with severe lower limb pain. This exemplifies Delivra's unique technology, with its multi-laminar systems which is capable of gradually releasing the active ingredient to the area of need, yielding quicker and longer lasting relief.
"This impressive data further validates Delivra's platform technology, offering patients an effective, safe and convenient over-the-counter cream for varicose vein treatment. Our robust over-the-counter product development and pharmaceutical pipeline of high-value innovative products provide an array of unique commercialization opportunities. LivReliefTM Varicose Vein Cream, along with LivReliefTM Pain Relief Cream, LivReliefTM Extra Strength Chronic Angry Pain Relief Cream and LivReliefTM Sports & Active Pain Relief Cream can be found in over 6,000 retail outlets across Canada ," said Dr. Joseph Gabriele , CEO of Delivra.
I’m pained to say I almost agree with your sentiments and have reverted to a majority ‘Hope’ position. I’ve been searching for the silver lining in this Dark cloud, through the financials, management strategy and IP. The IP I think presents the greatest value, but the execution is...
Patiently waiting.
Ouch!
Delivra publishes positive results using its platform technology for topical Advil™ (ibuprofen) and Celebrex™ (celecoxib)
http://www.stockhouse.com/news/press-releases/2018/12/17/cgx-energy-announces-definitive-rig-agreement-for-use-of-the-ralph-coffman-rig
CNW Group
December 11, 2018, 8:00 AM AST
TORONTO , Dec. 11, 2018 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company") today announced the publication of positive data from a pre-clinical study demonstrating the safety and efficacy to treat pain directly with a topical version of Advil™ (ibuprofen) and Celebrex™ (celecoxib). Testing for effects on joint pain and inflammation; topical Delivra-ibuprofen and Delivra-celecoxib formulations offer sustained long-term pain and swelling reduction, compared to oral equivalents. These results were published in the respected peer-reviewed scientific journal, Journal of Pain Research, under the title, "Penetration and efficacy of transdermal NSAIDs in a model of acute joint inflammation". The article may be found at the following link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6239099/?report=reader
In pre-clinical testing, undertaken by an independent third-party research organization, the Delivra-ibuprofen and Delivra-celecoxib formulations provided sustained pain reduction. In the study, both Delivra formulations were tested in an acute dog model of arthritis where the formulation performed equally or better for swelling and pain reduction compared its oral equivalent and test controls. This exemplifies Delivra's technology, with its multi-laminar system, is capable of gradually releasing the active ingredient to the area of need. This transdermal, designed "slow release" is a valuable and highly advantageous characteristic of the topical Delivra-ibuprofen and Delivra-celecoxib creams and may offer significant advantages over oral medication. These formulations will provide better localization of the drug at the site of need, yielding quicker and longer lasting relief.
"This impressive data further validates Delivra's platform technology by outperforming oral delivery and offering patients an effective, safe and convenient cream for pain management. Our robust pharmaceutical pipeline of high-value innovative products, including Delivra-ibuprofen and Delivra-celecoxib formulations, provide an array of unique commercialization opportunities. As such, we will continue to pursue out-licensing opportunities for major global markets to unlock the value of our portfolio," said Dr. Joseph Gabriele , CEO of Delivra.
For these two formulations, the Company has two PCT patent pending applications.
Frost Bank Chooses Martello for Better Control of IT Environment
https://www.newswire.ca/news-releases/frost-bank-chooses-martello-for-better-control-of-it-environment-702924081.html
Leading Texas bank renews its contract for three years, following an eight year history of meeting IT operations management challenges with Savision software.
OTTAWA, Dec. 17, 2018 /CNW/ - ("Martello") (TSXV: MTLO), a leading provider of network performance management solutions for real-time communications, announced today that , a Texas-based chartered bank that is among the largest banks in the United States, has chosen to renew its contract for the IT operations management software products for the next three years. This follows an eight year relationship in which Frost Bank has continually expanded its Savision product coverage, bringing all of the bank's IT and performance monitoring capabilities into a single dashboard. Savision is a wholly owned subsidiary of Martello.
Our Family of Four is officially your Island Guest this evening. We landed at Princess Juliana this afternoon to a very warm welcoming. Sort of a home coming, as we are accommodated by Family for our stay.
(Plug) where can a fellow sample Canopy Growth finest on this beautiful Island? No where, I know. But something similar? Strange now going from Legal Status Cannabis Canada, Transfering through ReeferMaddness America, and now Island vibe Prohibition. I can bet the 20k visitors coming off the Caribbean Cruise Line would really appreciate a Tweed n’ Tonic at the Duty Free, or a selection of Premium Flower or Prerolled for the 6 o’clock sunset.
Any to do recommendations for visitors?
Cheers Neighbor
If you build it, will they come?
How many “units” has Canopy shipped since oct 17th?
Why has Canopy hired a PHD in engineering for its pre rolled products, as opposed to outsourcing this service or making equity deals with Tobacco Firms?
When the smoke clears and the Big Box retailers serving 350m people have a demand for a new trendy stable beverage, which corporation can deliver the earliest?
What might revenues look like?
Straight, the expenses were big, nearly half a B. What were they for?
There’s a huge tech IP side to this that other LP’s are paying for in Margins or a complete failure of market penetration. This is not the case with Canopy.
Vertical integration.
Seed To Sale.
That is a vast market.
But I’m not an Educated Financial Analyst. I just read stuff published by other people and decide from there.
Wow! this is a silent ticket making big waves
Farm bill headed to Trump after landslide House approval
By HELENA BOTTEMILLER EVICH and CATHERINE BOUDREAU
12/12/2018 04:27 PM EST
The House on Wednesday easily passed the compromise farm bill by a vote of 369-47, sending the sweeping agriculture and nutrition measure to President Donald Trump to sign.
https://www.politico.com/story/2018/12/12/house-passes-farm-bill-1060916
Only one chicken scratch signature remaining.
Speculation: I wonder if there are any National Financial institutions is USA that might be scouting to play ball with Canopy? Now that this Hemp derived CBD corner is passing the apex, accelerated institutional investments on the horizon IMO. Like the BMO deal maybe?
House passes $867 billion farm bill, sending it to Trump
By Juliegrace Brufke
December 12, 2018 - 04:16 PM EST
Trump: Farm bill 'in very good shape'
https://thehill.com/homenews/house/420990-house-passes-867-billion-farm-bill-sending-it-to-trump
is your Photograph in Sint Maartin JohnCm? is that where you reside?
(PLUG)Canopy is leading discussions in the Caribbean also.
View from the C-Suite: Dr. Joseph Gabriele, Chief Executive Officer, Delivra Corp., tells his company's story. Filmed on November 27, 2018
https://finance.yahoo.com/news/view-c-suite-dr-joseph-174300972.html?.tsrc=applewf
Thank You. Greatly Appreciated. SNAP seems to be the sticky subject as I understand. Kind of interesting to see how the two sides of the political spectrum kind of trading places is support of the Bill.
Would you please share your sentiments on the progress and timeline expectations of the Farm Bill.
Martello Receives Two 2018 Best Ottawa Business Awards (BOBs)
PRNewswire FOLLOW
November 19, 2018 3:13pm Comments
Company Awarded Private Equity Deal of the Year and Best Business
OTTAWA, Nov. 19, 2018 /CNW/ - Martello Technologies Group Inc. ("Martello") (TSXV:MTLO), a leading provider of network performance management solutions for real-time communications, accepted two awards from the 2018 Best Ottawa Business Awards (BOBs) for "Deals of the Year: Private Equity" and "Best Business". The awards were presented at the BOBs gala on Friday, November 16th at the Westin Ottawa.
https://www.benzinga.com/pressreleases/18/11/r12726377/martello-receives-two-2018-best-ottawa-business-awards-bobs
Delivra Achieves Record Third Quarter 2018 Revenues
CNW Group
CNW GroupNovember 19, 2018, 7:00 AM EST
https://finance.yahoo.com/news/delivra-achieves-record-third-quarter-120000789.html?.tsrc=applewf
TORONTO , Nov. 19, 2018 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company") reported its financial results for the three and nine months ended September 30, 2018 . All figures are reported in Canadian dollars ($), unless otherwise indicated. Delivra's financial statements are prepared in accordance with International Financial Reporting Standards.
Highlights for the Third Quarter and Year-To-Date 2018:
Achieved record revenues of $1,670,077 for the quarter and $3,976,861 for the year-to-date, representing an 81% and 21% growth over the comparative periods, respectively;
Successfully launched two new LivReliefTM products during the quarter which have begun selling on retailer shelves, LivReliefTM Extra Strength Chronic Angry Pain Relief Cream and LivReliefTM Sports & Active Pain Relief Cream;
Re-branded and re-packaged the LivReliefTM family of products during the quarter, which is now available at retail stores;
Increased the number of retail locations currently selling LivReliefTM products from 5,200 stores at the beginning of the year to over 6,000 retail locations as of today;
Developed a revolutionary, proprietary topical cream base therapeutic, DelivraTMN, for molecules of cannabis, cannabis-like and opioids, for a safer more targeted and consistent delivery to patients afflicted with chronic pain and anxiety;
Positive results received on the ability to treat pain directly with a topical version of AdvilTM (ibuprofen). Testing for effects of joint pain and inflammation, topical Delivra-ibuprofen formulation offers long-term pain and swelling reduction compared to oral ibuprofen;
Signed a joint venture agreement with Intervivo Solutions for a ready to market sleep and anti-anxiety topical therapeutic cream for the animal health industry. Our expertise in formulation using our innovative delivery system platform combined with Intervivo's success in demonstrating pharmacokinetic, safety and efficacy data in clinically relevant canine and feline models provides a unique platform for rapid development of transdermal commercial products for the veterinary market;
Founder and CEO, Dr. Joseph Gabriele , received the Ernst & Young Entrepreneur of the Year 2018 Ontario award in the Health Care category; and
Due to recently received inquiries from a number of interested parties in relation to the Company`s proprietary transdermal delivery system platform, Delivra engaged Canaccord Genuity Corp. to act as exclusive financial advisor to review, identify, analyze and explore the range of strategic and other opportunities available to the Company within the cannabis and pharma industries. There can be no assurance that the Company will enter into any transaction, that there will be any change in the operation or ownership of the Company, or that the Company will take any other corporate action as a result of the review.
Canopy VC arm ready to pounce if U.S. legalizes marijuana
By Kristine Owram
Bloomberg
Mon., Nov. 19, 2018
https://www.thestar.com/news/cannabis/2018/11/19/canopy-vc-arm-ready-to-pounce-if-us-legalizes-marijuana.html
Canopy Growth Corp.’s venture capital arm is barred from investing in the U.S. pot market, but its founders are ready to take advantage of “the most compelling opportunity in the history of capitalism,” if federal laws change.
Like many of its peers, Canopy Rivers Inc. has to steer clear of U.S. marijuana investments because its Canadian listing requires that issuers comply with federal laws in the jurisdictions where they operate. Although cannabis is legal in several states, it remains illegal at the federal level.
Canopy Rivers Portfolio Company Radicle Receives Licence From Health Canada to Commence Sales of Premium Craft Cultivated Product
Canopy Rivers Corporation
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRES
https://globenewswire.com/news-release/2018/11/19/1653551/0/en/Canopy-Rivers-Portfolio-Company-Radicle-Receives-Licence-From-Health-Canada-to-Commence-Sales-of-Premium-Craft-Cultivated-Product.html
TORONTO, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Canopy Rivers Inc. (“Canopy Rivers” or the “Company”) (TSXV:RIV) congratulates its portfolio company, Radicle Medical Marijuana Inc. (“Radicle”), on receiving its production and sales licence from Health Canada. The licence will allow Radicle to supply and sell finished cannabis products for both the medical and adult-use market in Canada.
First licensed for cultivation in early 2018, Radicle’s 140,000 square foot indoor facility located in Hamilton, ON is focused on small-batch cultivation of unique genetic strains using proprietary and sustainable growth methods. In August 2018, Radicle was one of the original twenty-six licensed cannabis producers selected in a highly competitive product call by the Ontario Cannabis Store for recreational sale online and one of two entities selected despite only having a licence to cultivate at the time. Radicle recently launched Gage Cannabis Co., a new premium brand in the craft cannabis segment.
“We are very proud to be part of the Radicle story,” said Daniel Pearlstein, EVP Strategy at Canopy Rivers. “This latest milestone marks a new and exciting chapter for Radicle and strengthens our confidence in their commitment to deliver premium, small-batch, handcrafted cannabis.”
Canopy Rivers first invested in Radicle in August 2017. The grant of the sales licence has triggered the conversion of Canopy Rivers’ convertible debenture into approximately 24% of the fully diluted issued and outstanding common shares of Radicle. Further, Canopy Rivers’ repayable debenture has been automatically set-off against consideration otherwise payable entitling Canopy Rivers to a royalty interest with a minimum annual payment of $900,000 per year for a term of 20 years. For more information regarding the Company’s investment in Radicle, please refer to the joint management information circular (the “Circular”) of Canopy Rivers Corporation and the Company dated August 8, 2018, filed with Canadian securities regulators and available on the Company’s profile on SEDAR at www.sedar.com.
Martello Appoints Mike Galvin and Jennifer Camelon to its Board of Directors
https://www.newswire.ca/news-releases/martello-appoints-mike-galvin-and-jennifer-camelon-to-its-board-of-directors-700362421.html
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES./
OTTAWA, Nov. 13, 2018 /CNW/ - (TSXV: MTLO), ("Martello" or the "Company"), a leading provider of network performance management solutions for real-time communications announced today the appointments of Mike Galvin and Jennifer Camelon to its board of directors. Mr. Galvin is a telecommunications industry leader with more than 32 years' experience in BT PLC, who has been responsible for the design, deployment and management of some of the largest broadband networks in the UK. Ms. Camelon is a technology industry finance and business executive with experience leading global transformation and integration initiatives for organizations such as QNX and the Royal Canadian Mint. All current Directors remain on Martello's Board. These appointments bolster Martello's leadership team following the Company's , as Martello continues to execute on its 'build and buy' growth strategy.
Mr. Galvin has been responsible for the design, deployment and management of some of the largest broadband networks in the UK. As Managing Director in BT PLC, Mr. Galvin led key national initiatives including the rollout of BT's fibre network, and the nationwide delivery of high-speed internet for the UK. Mr. Galvin has led BT's internationally respected research division. A telecommunication engineer and specialist in broadband networks he has 32 years of industry experience, working at board level, with governments and in leadership positions in technology, innovation and research. Mr. Galvin brings extensive technology program leadership experience and delivery of large infrastructure projects in both the public and private sectors.
Currently the interim president and CEO of the Royal Canadian Mint, Ms. Camelon is a seasoned finance and business leader. Previously Chief Financial Officer of QNX Software systems, Ms. Camelon also led the IT, operations and quality functions. Ms. Camelon was the primary corporate representative to QNX's parent companies including Research in Motion. In addition to her responsibilities at QNX, she regularly undertook special projects and additional responsibilities in support of BlackBerry's transformation efforts. Prior to QNX, Ms. Camelon worked for Delta Hotels and Resorts as well as Price Waterhouse in both Toronto and Ottawa. Ms. Camelon is a Chartered Professional Accountant (CPA, CA) and holds a Bachelor of Commerce (Honours) from Queen's University. In 2005 the Ottawa Business Journal recognized Ms. Camelon as one of the Top 40 under 40.
"On behalf of the Martello Board of Directors, I am pleased to welcome Mr. Galvin and Ms. Camelon to the team", said Terry Matthews, Co-Chairman of Martello and Chairman of Wesley Clover International. "Their global technology, business and transformation expertise will be valuable to Martello as the Company moves into the next phase of growth".
"I'm excited about this opportunity to work with a high calibre team seeking to dominate the market for network and IT performance management", said Mr. Galvin. "I look forward to helping Martello accelerate its growth in the global enterprise networking market".
"Martello is poised to expand with a strong global customer base and an aggressive strategy for growth as a public company", said Ms. Camelon. "Having worked extensively leading similar growth and transformation initiatives, I look forward to working with Martello's leadership to achieve best in class outcomes".
"I'm pleased to welcome Mr. Galvin and Ms. Camelon to Martello's world-class board of directors", said John Proctor, president and CEO of Martello. "I look forward to working with both to accelerate Martello's growth strategy".
Martello has a positive track record in acquisition activity. On November 2, the company announced the completion of its , after having acquired SD-WAN player Elfiq Networks in December 2017 and Netvitesse in 2014. The Company's solutions have been recognized by the industry. In September, Martello received a and ranked as Ottawa's Fastest Growing Company, at No. 28 on the Growth 500 list of Canada's Fastest Growing Companies. The Company's debut on the TSX Venture Exchange (TSXV) followed the closure of an oversubscribed $7.5 million private placement in June 2018.
Martello Appoints Mike Galvin and Jennifer Camelon to its Board of Directors
https://www.newswire.ca/news-releases/martello-appoints-mike-galvin-and-jennifer-camelon-to-its-board-of-directors-700362421.html?utm_sq=fx6q6fz1de&utm_source=Twitter&utm_medium=social&utm_campaign=MartelloTech&utm_content=PressRelease
OTTAWA, Nov. 13, 2018 /CNW/ - Martello Technologies Group Inc. (TSXV: MTLO), ("Martello" or the "Company"), a leading provider of network performance management solutions for real-time communications announced today the appointments of Mike Galvin and Jennifer Camelon to its board of directors. Mr. Galvin is a telecommunications industry leader with more than 32 years' experience in BT PLC, who has been responsible for the design, deployment and management of some of the largest broadband networks in the UK. Ms. Camelon is a technology industry finance and business executive with experience leading global transformation and integration initiatives for organizations such as QNX and the Royal Canadian Mint. All current Directors remain on Martello's Board. These appointments bolster Martello's leadership team following the Company's acquisition of Savision, as Martello continues to execute on its 'build and buy' growth strategy.
For any ACMPR/Spectrum Cannabis Patients: James E Wagner Cannatonic Bud is Very Good Quality. One of the smoothest CBD strains I have ever tired. Its a little more expensive than others, but more than worth it. The grow platform at Wagner is 100% Aeroponic, and they've just been listed under the craft grower at Canopy/Spectrum. Ordered it Yesterday, received it today. Excellent.
As far as Feb 2019 goes, I can now see why so many LP's will suffer financially towards that date. The regulations require an Lp to complete 2 grow cycles of a strain , tested, the full 9, in order to get a sales license. so this would be Wagners 3rd, I assume, under the guidance of Canopy. Other small Lp's without this support man not be ready on the third go...so
Not to throw salt on any recent wounds, check out this decrepit analysis about the first quarter of 2019.
http://www.bnnbloomberg.ca/video/brian-acker-discusses-canopy-growth~1530539
$3!
Sheesh!
Nightmarish scenario. I can't even begin to understand the logic.
I placed an order on OCS.ca yesterday Nov.4 in the PM ( #19552X), and this evening about 24 hrs later, I got an emailed update;"order processed" and " on its way". Seems like the e-commerce has been sorted out at the OCS/Canada Post Services (although rating job action is still taking place). . Checked the tracking number and Canada Post has it listed "in transit". The first and second orders I placed at the opening and close of midnight Oct 17 (#'s 12K and 100K respectively ) took over a week to receive the notice of shipment and tracking number and a few more days to receive it. Many people would have been waiting for the initial orders before considering making another. Also, the Canopy Strains left out of stock are now instock again. So it would seem like some wrinkles are being ironed out.... for now.
Spectrum Order Nov.5 ( 1,043,38X )
Martello Secures $3 Million in Loan Facilities from Royal Bank of Canada (RBC)
https://www.newswire.ca/news-releases/martello-secures-3-million-in-loan-facilities-from-royal-bank-of-canada-rbc-699432151.html
NEWS PROVIDED BY
Martello Technologies Group
Nov 02, 2018, 14:17 ET
Financing from leading Canadian commercial lender closed in conjunction with the acquisition of Savision
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES./
OTTAWA, Nov. 2, 2018 /CNW/ - Martello Technologies Group Inc. (TSXV: MTLO), ("Martello" or the "Company"), a leading provider of network performance management solutions for real-time communications announced today that it has closed a financing with Royal Bank of Canada (RBC) for new loan facilities through its subsidiary Martello Technologies Corporation (the "Loan"). The financing includes a term loan of $3 million, in conjunction with the acquisition of Savision B.V.
This new financing is comprised of a term loan, a revolving facility and other ancillary facilities. The term loan of $3 million bears an interest rate of 5.40% per annum and is repayable over a term of 36 months. The revolving facility, in the amount of up to $1 million, bears a variable interest rate based on the RBC prime rate and is repayable on demand.
The facilities are secured by a general security agreement on the property of Martello Technologies Corporation, a subsidiary of the Company, as well as secured guarantees from five other subsidiaries of the Company and the Company itself.
"This loan facility from Royal Bank of Canada will solidify our foundation for growth and help fuel Martello's 'build and buy' strategy, which includes the acquisition of Savision", said John Proctor, president and CEO of Martello. "We appreciate the confidence placed in us by one of Canada's largest commercial lending institutions".
Recent acquisition activities for Martello include the acquisition of Savision B.V. announced in October 2018, after having acquired Elfiq Networks in December 2017 and Netvitesse in 2014. The Company's solutions have also been recognized by the industry. In September, Martello received a Frost & Sullivan Leadership Award for NPM (Network Performance Management) and ranked as Ottawa's Fastest Growing Company, at No. 28 on the Growth 500 list of Canada's Fastest Growing Companies. The Company recently went public with a TSXV listing, following the closure of an oversubscribed $7.5 million private placement.
Canopy Rivers Congratulates Portfolio Company James E Wagner as It Launches Product Sales on Spectrum Cannabis Platform
GlobeNewswire
November 1, 2018, 7:00 AM EDT
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRES
https://finance.yahoo.com/news/canopy-rivers-congratulates-portfolio-company-110000775.html?.tsrc=applewf
TORONTO, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Canopy Rivers Inc. (“Canopy Rivers” or the “Company”) (RIV.V) congratulates its portfolio company, James E. Wagner Cultivation Ltd. (“JWC”) (JWCA.V), on the selection and sales launch of its dried cannabis products on the Spectrum Cannabis online marketplace.
JWC is a participant in Canopy Growth Corporation’s (“Canopy Growth”) (TSX:WEED, NYSE:CGC) CraftGrow program which is designed to distribute high quality cannabis grown by a diverse set of producers through Canopy Growth’s broader distribution platform. JWC is the first entirely aeroponic licensed producer of cannabis in Canada, and its unique growing model combines craft cannabis production practices with proprietary technology to produce high quality flower. The first product expected to be offered on the Spectrum site is JWC’s high-CBD strain “Cannatonic”.
Centric Health to Host Third Quarter 2018 Financial Results Conference Call/Corporate Presentation on Wednesday, November 14, 2018 at 8:30 a.m. (ET)
http://www.stockhouse.com/news/press-releases/2018/10/30/centric-health-to-host-third-quarter-2018-financial-results-conference-call
TORONTO, Oct. 30, 2018 /CNW/ - Centric Health Corporation ("Centric Health" or "the Company") (TSX: CHH) today announced that it will host a conference call, including a slide presentation, to discuss its third quarter 2018 financial results on Wednesday, November 14, 2018 at 8:30 a.m. (ET). The Company expects to report its third quarter 2018 financial results via news release after markets close on Tuesday, November 13, 2018.
Telephone Dial-In Access Information
To access the conference call by telephone, dial 647-427-7450 or 1-888-231-8191. Please connect approximately 10 minutes prior to the beginning of the call to ensure participation. Those participating in the conference call by telephone can view the slide presentation by accessing the online webcast (see instructions below) and choosing the Non-Streaming Audio option.
Webcast Access Information
A live webcast of the conference call, including the slide presentation, will be available on the Events and Presentations page of the Investors section of the Company's web site (http://www.centrichealth.ca/investors/events-and-presentations.html). Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. To view the webcast presentation with slides, please choose either the Real Streaming Audio or Windows Streaming Audio option.
Archive Access Information
The conference call will be archived for replay by telephone until Wednesday, November 21, 2018 at midnight. To access the archived conference call, dial 416-849-0833 or 1-855-859-2056 and enter the reservation number 6158469.
The webcast with slide presentation will be archived for 90 days on the Events and Presentations page of the Investors section of the Company's web site (http://www.centrichealth.ca/investors/events-and-presentations.html).
Ernst & Young Names Dr. Joseph Gabriele of Delivra - Entrepreneur of the Year 2018 Ontario Award in the Health Care Category
CNW Group
October 30, 2018, 7:00 AM EDT
TORONTO , Oct. 30, 2018 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company"), a science and biotechnology company, today announced that its Founder and CEO, Dr. Joseph Gabriele , is the recipient of the Ernst & Young Entrepreneur Of The Year 2018 Ontario award in the Health Care category.
https://finance.yahoo.com/news/ernst-young-names-dr-joseph-110000102.html?.tsrc=applewf
"I'm humbled and honoured by the award", said Joseph Gabriele . "I'm grateful to the Delivra team who are the true heroes. I'm proud that EY has recognized the capabilities of our unique patented delivery system, DelivraTM, for pharmaceutical and natural molecules across a spectrum of medical and consumer products capabilities. Delivra was born out of a need to help my wife who was debilitated by post-surgery pain, hence the genesis of our novel topical solution. She feared the addictive powers of opioids and couldn't take oral medications due to digestive challenges. Today, Delivra helps many pain suffers in Canada and internationally. We also have an over-the-counter product line, called LivReliefTM, and just launched a new Extra Strength Chronic Angry Pain cream, as well as a unique new Sports & Active cream. In our pharmaceutical division, we are helping patients that are suffering with pain related to medical issues, including diabetes, and we have the capability of delivering cannabis and CBD to both humans and animals, topically and effectively. Our mission is to help pain sufferers reclaim their lives back. We are excited about the future and our proven capability and potential to help millions of people."
"Companies in the health care sector face a challenging and competitive landscape," says Paula Smith , EY Entrepreneur Of The Year Ontario Program Co-Director. " Canada , in particular, has an aging population and growing demand for patient care, pushing entrepreneurs to respond quickly and thoughtfully with innovative solutions to meet changing needs."
"Delivra is doing just that," adds Elena Doucette , EY Entrepreneur Of The Year Ontario Program Co-Director. "They're revolutionizing the delivery of pain relief, and doing it in a safer and more effective way for those in need. We're proud to have recognized the outstanding work Joseph is doing in the health care sector."
ABOUT DELIVRA CORP.
Delivra Corp. is a specialty biotechnology company having a proprietary transdermal delivery system platform that can shuttle pharmaceutical and natural molecules through the skin, in a targeted manner. Delivra manufactures and sells a growing line of natural topical creams with the proprietary transdermal delivery system platform under the LivReliefTM brand, for conditions such as joint and muscle pain, nerve pain, varicose veins, wound healing, and under the LivSportTM brand for sports performance. LivReliefTM products are available in pharmacies, grocery chains, and independent health food stores across Canada , including, but not limited to, Shoppers Drug Mart, Walmart, Loblaw, Rexall, Pharmasave, London Drugs, and on-line at www.livrelief.com. In parallel with its consumer products business, Delivra also has a mandate to license its patent-pending, proprietary transdermal delivery technology platform to pharmaceutical companies globally, for the repurposing of pharmaceutical molecules transdermally to treat a broad range of conditions, along with licensing its over-the-counter products globally. Delivra is headquartered in Hamilton, Ontario and has a research and development laboratory in Charlottetown, Prince Edward Island .
Further information on Delivra can be found at www.delivracorp.com and www.livrelief.com.
About EY Entrepreneur Of The Year®
EY Entrepreneur Of The Year® is the world's most prestigious business awards program for entrepreneurs. The program makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global awards program of its kind, Entrepreneur Of The Year celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 145 cities in more than 50 countries. ey.com/ca/EOY
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Delivra Corp
View original content: http://www.newswire.ca/en/releases/archive/October2018/30/c6811.html
LiveWell Canada and Vitality Sign Major CBD Supply Deal with U.S. Private Equity Firm
CNW Group
October 30, 2018, 7:00 AM EDT
/NOT FOR DISSEMINATION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES /
https://finance.yahoo.com/news/livewell-canada-vitality-sign-major-110000214.html?.tsrc=applewf
Minimum quantity of 1,000 Kgs per month to ramp up to 3,000 Kgs per month
OTTAWA , Oct. 30, 2018 /CNW Telbec/ - LiveWell Canada Inc. ("LiveWell" or the "Company"), (LVWL.V) (LXLLF), is pleased to announce that it has partnered with Vitality CBD Natural Health Products Inc, a Canadian CBD company, (collectively the "Suppliers") to sign a binding term sheet ("Term Sheet") with Global Wellness Distributors, LLC ("Global Wellness"), a Nevada entity controlled by a U.S. private equity firm, for the supply of cannabidiol (CBD) wholesale products in North America .
LiveWell Canada and Vitality Sign Major CBD Supply Deal with U.S. Private Equity Firm
CNW Group
October 30, 2018, 7:00 AM EDT
/NOT FOR DISSEMINATION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES /
https://finance.yahoo.com/news/livewell-canada-vitality-sign-major-110000214.html?.tsrc=applewf
Minimum quantity of 1,000 Kgs per month to ramp up to 3,000 Kgs per month
OTTAWA , Oct. 30, 2018 /CNW Telbec/ - LiveWell Canada Inc. ("LiveWell" or the "Company"), (LVWL.V) (LXLLF), is pleased to announce that it has partnered with Vitality CBD Natural Health Products Inc, a Canadian CBD company, (collectively the "Suppliers") to sign a binding term sheet ("Term Sheet") with Global Wellness Distributors, LLC ("Global Wellness"), a Nevada entity controlled by a U.S. private equity firm, for the supply of cannabidiol (CBD) wholesale products in North America .
Logo: LiveWell Canada (CNW Group/LiveWell Canada Inc.)
Logo: LiveWell Canada (CNW Group/LiveWell Canada Inc.)
Under the Term Sheet dated October 27, 2018 , which covers a period of 15 months with an option for four renewable one-year terms, Global Wellness commits to distribute CBD isolate, distillate and full spectrum CBD oil. At closing, Global Wellness will pay a US$3 million deposit to the Suppliers for the initial CBD supply. Commencing in January 2019 , Global Wellness will distribute a minimum quantity of 1,000 kilograms per month. Starting April 2019 to March 2020 , the minimum quantity increases to 3,000 kilograms per month, for a total minimum quantity of 39,000 kilograms over the 15-month contract period.
LiveWell and Global Wellness will work together to market and sell CBD products in North America , leveraging sales expertise and operational support in both organizations. The parties will co-share net profits on all sales. Based on current observable wholesale market pricing, CBD isolate pricing ranges between US$6,500 to US$10,000 based on the quality and purchase volume of the CBD purchase order.
All CBD products being supplied under the Term Sheet will be derived from industrial hemp and contain no more than 0.3% THC content, making it suitable for the health and wellness market. As legalization and acceptance of CBD -- the non-psychoactive cannabis compound -- accelerates at a rapid pace globally, the demand for CBD products to improve health and wellness is exploding. LiveWell has conducted major research on CBD and is investing in technologies for the extraction and isolation of CBD and other cannabinoids for use in prescription and consumer health products.
"For some time now LiveWell has been quietly positioning itself to become a significant supplier of wholesale CBD to global companies looking to launch a multitude of CBD products. We recognized early on that if these companies were to enter the marketplace, a large scale, reliable source of CBD would be required, and we have assembled the assets and partnerships to provide it," said David Rendimonti , President and CEO of LiveWell. "This is one of several partnerships we have developed that allows LiveWell to generate significant revenues at a nominal cost and no outlay of capital."
The Term Sheet is subject to customary due diligence and execution of a definitive agreement by November 30, 2018 .
About CBD
CBD is the same molecule whether it comes from cannabis or hemp. However, CBD derived from hemp is more economical to produce and has a larger global market potential due to less stringent regulations worldwide for hemp. The Brightfield Group of Chicago estimates the North American market for CBD from hemp could reach US$22 billion by 2022. However, the global market could be significantly larger. Several European countries have already legalized hemp, and the World Health Organization has also recommended that CBD be descheduled across 194 nations.
About Global Wellness Distributors, LLC
Headquartered in Las Vegas, Nevada , Global Wellness Distributors, LLC ("Global Wellness") is a new large-scale distributor of compliant hemp products, including CBD Isolate, CBD Distillate and full spectrum hemp-derived oil. The Global Wellness team consists of accomplished industry veterans whose substantial experience in the cannabis and hemp markets throughout the United States and Canada , including California , Colorado , Kentucky , and Oregon , is focused on aggregating large-scale hemp supply for distribution to identified scale buyers.
The Global Wellness team maintains strategic partnerships with domestic and international industry leaders to provide the most competitive and affordable supply solutions available to help ensure success for companies in the industrial hemp and CBD marketplace. Global Wellness' management team brings decades of industry experience to the forefront of the ever-growing global hemp economy and are differentiated in the marketplace by their process-driven operating principals and high degree of professionalism.
About LiveWell Canada
LiveWell Canada Inc. (TSXV:LVWL, OTC: LXLLF) is an innovative cannabis and hemp company focused on advanced research on CBD and other cannabinoids, as well as developing and distributing prescription and consumer health and wellness products. The company has greenhouses under construction located in Ontario and Québec and is supported by business partners such as Canopy Growth (TSX: WEED, NYSE: CGC) and Canopy Rivers (RIV.V). For more information, visit livewellcorp.com.
About Vitality
Vitality CBD Natural Health Products Inc. ("Vitality") is a privately-owned Canadian company. Through its wholly-owned subsidiary, it is a fully integrated, hemp processing and CBD isolation and wholesaling company. Vitality has just harvested over 21,000 acres of industrial hemp, purposely planted for CBD production. It has operations in Eureka, Montana under the State Farm Act with licenses to cultivate, process and market CBD in the United States . Vitality is currently producing CBD isolate in its Eureka facility in its commercial demonstration plant and is building full-scale manufacturing facilities that will increase production to over 3,000 kilograms per day of CBD isolate.
Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements about the Company and its business. Often, but not always, forward-looking statements can be identified by the use of words such as "plan", "continue", "expect", "schedule", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements (including negative variations) that certain events or conditions "may" or "will" occur. Such statements are based on the current expectations of management. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of unknown and known risk factors and uncertainties affecting the Company. Further, the Company cautions that this foregoing list of material factors is not exhaustive, and readers are encouraged to read all Risk Factors disclosed in the Company's Management Discussion & Analysis dated October 26, 2018 .
In respect of the forward-looking statements and information concerning the anticipated benefits and completion of the Term Sheet, including the anticipated timing for completing the definitive agreement, the Company has provided such statements and information in reliance on certain assumptions that it believes are reasonable at this time. Further, there can be no assurance that the transaction contemplated under the Term Sheet will occur, or that it will occur on the terms and conditions contemplated in this news release. Following the due diligence, the Transaction could be modified, restructured or terminated.
The forward-looking information contained in this press release represents expectations of the Company as of the date of this press release and accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While the Company may elect to, it does not undertake to update this information at any particular time except as required in accordance with applicable securities laws.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
For more information, visit livewellcorp.com.
SOURCE LiveWell Canada Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/October2018/30/c7201.html
Dear Xxxxxxx,
Thank you for placing Order 9928x with the OCS. I apologize for the delay in getting your package to you.
Our staff have been working around the clock to fulfill customer orders – we have received over 150,000 orders since legalization.
The huge volume and complications related to rotating strikes and mail backlogs at Canada Post will mean longer-than-expected delivery times for some people.
While many orders have been shipped, customers will continue to see delivery times that are longer than anticipated. Please rest assured that you will receive a Canada Post tracking number when your order is ready to ship.
The OCS has taken steps to increase capacity at our processing facility to help meet this great demand so that we can get more packages out to customers.
I thank you for your patience as we continue to process orders. We are committed to the highest standard of customer service, and we are taking steps to ensure we can achieve this standard.
Sincerely,
Patrick Ford
President, Ontario Cannabis Store
View from the C-Suite: Bruce Linton, CEO, Canopy Rivers Inc., tells his company's story. Filmed on October 15, 2018
Canada NewsWire
TORONTO, Oct. 23, 2018
TORONTO, Oct. 23, 2018 /CNW/ -
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20181023:nCNW1VJSMa